Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment

• Published in: Clinical pharmacology in drug development 2019-11, Vol.8 (8), p.1053-1061
• Main Authors: Ng, Juki, Duan, W. Rachel, Marbury, Thomas, Schmidt, Jeffrey M., Klein, Cheri E.
• Format: Article
• Language: English
• Subjects: elagolix; endometriosis; GnRH antagonist; hepatic impairment; Hormones; Kidneys; Liver; Pharmacokinetics; Pharmacology; renal impairment; Womens health
• ISSN: 2160-763X; 2160-7648
• DOI: 10.1002/cpdd.640

The aim of these studies was to assess the safety and pharmacokinetics of elagolix, an oral nonpeptide gonadotropin‐releasing hormone antagonist following oral administration in women with renal or hepatic impairment. Two phase 1 studies were conducted in adult women with normal renal function versus renal impairment (reduced study), and normal hepatic function versus hepatic impairment (full study design). All women received a single dose of elagolix 200 mg (renal) or 150 mg (hepatic). Intensive pharmacokinetic blood samples were collected. Elagolix exposures were comparable in women with normal renal function and those with moderate/severe renal impairment or end‐stage renal disease. Elagolix exposures also appeared to be similar in women with normal hepatic function and women with mild hepatic impairment. Elagolix area under the curve in women with moderate hepatic impairment and with severe hepatic impairment was approximately 3‐fold and 7‐fold higher than in women with normal hepatic function. The adverse event incidence was low, with the main events being mild nausea and headache. No dosage adjustment was needed in women with renal impairment or women with mild hepatic impairment. Although an elagolix dose of 150 mg once daily may be used in women with moderate hepatic impairment for up to 6 months, this elagolix dose should not be used in women with severe hepatic impairment.